Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q2 2026 › vs Q2 2025
Arcturus Therapeutics Holdings (ARCT) Q2 2026 vs Q2 2025 (year over year)
Arcturus Therapeutics Holdings's revenue fell $25.3M (-90%) from $28.3M in Q2 2025 to $3.0M in Q2 2026. The biggest changes: Collaboration Revenue −$23.6M (-96%); Grant −$1.7M (-45%).
Arcturus Therapeutics Holdings, Q2 2026: revenue $3.0M (-90% year over year), operating margin -863.3%, net loss $23.8M, operating cash flow −$19.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Grant | $2.1M | $3.8M | −$1.7M | -45% |
| Collaboration Revenue | $880K | $24.5M | −$23.6M | -96% |
| Revenue | $3.0M | $28.3M | −$25.3M | -90% |
| Other income, net | $1.8M | $2.4M | −$680K | -28% |
| Net loss | $23.8M | $9.2M | $14.6M | +159% |
| Costs & expenses | $28.5M | $39.9M | −$11.4M | -29% |
| Operating costs | $28.5M | $39.9M | −$11.4M | -29% |
| Research & development | $17.5M | $29.6M | −$12.1M | -41% |
| General & admin | $11.0M | $10.3M | $651K | +6% |
| Operating cash sources | $24.7M | $12.8M | $12.0M | +94% |
| Depreciation & amortization | $600K | $800K | −$200K | -25% |
| Share-based compensation | $4.2M | $6.2M | −$2.0M | -32% |
| Cash used in operations | $19.9M | $5.8M | $14.2M | +246% |
| Net loss absorbed | $23.8M | $9.2M | $14.6M | +159% |
| Working capital & other | $956K | $3.6M | −$2.6M | -73% |
Questions
How much did Arcturus Therapeutics Holdings's revenue grow year over year in Q2 2026?
Arcturus Therapeutics Holdings's revenue fell $25.3M (-90%) from $28.3M in Q2 2025 to $3.0M in Q2 2026.
What drove Arcturus Therapeutics Holdings's revenue change in Q2 2026?
Collaboration Revenue −$23.6M (-96%); Grant −$1.7M (-45%).